SCHEMBL6482776

SCHEMBL6482776

CC(=O)Nc1ccc(-c2ccc(OC(C)CNS(=O)(=O)C(C)C)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA4 P48058 5/20 0.49
SMN1; SMN2 Q16637 2/20 0.47
HTT P42858 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MTNR1A P48039 2/20 0.46
MTNR1B P49286 2/20 0.46
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
CA9 Q16790 2/20 0.45
CA12 O43570 1/20 0.45
GRIA2 P42262 1/20 0.44
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43
LMNA P02545 2/20 0.43
CYP1A2 P05177 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
ADRB2 P07550 1/20 0.43
ADRB1 P08588 1/20 0.43
ADRB3 P13945 1/20 0.43
OPRK1 P41145 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6480681 0.89 GRIA4 (0.48) GRIA4MTNR1AMTNR1BCA1CA2
SCHEMBL6482318 0.87 GRIA4 (0.53) GRIA4MTNR1AMTNR1BGRIA2CYP1A2
SCHEMBL6482779 0.84 SMN1; SMN2 (0.44) SMN1; SMN2HTTL3MBTL1MTNR1AMTNR1B
SCHEMBL6475284 0.83 GRIA4 (0.53) GRIA4SMN1; SMN2MTNR1AMTNR1BCA1
SCHEMBL6481138 0.83 MTNR1A (0.50) GRIA4MTNR1AMTNR1BKMT2AADAMTS4
SCHEMBL6480644 0.82 GRIA4 (0.66) GRIA4MTNR1AMTNR1BKMT2AMEN1
SCHEMBL6475291 0.81 GRIA4 (0.62) GRIA4MTNR1AMTNR1BGRIA2CYP1A2
SCHEMBL6474389 0.81 GRIA4 (0.62) GRIA4HTTMTNR1AMTNR1BGRIA2
SCHEMBL6482156 0.81 MTNR1A (0.52) GRIA4MTNR1AMTNR1BGRIA2
SCHEMBL6482278 0.81 ACACB (0.53) GRIA4SMN1; SMN2MTNR1AMTNR1BKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US claimed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US claimed
EP-1265857-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-2001068592-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-09-20 WO claimed
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US disclosed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225266-A1 Sulfonamide derivatives GRIN2A, GRM2, GRIA2 GRIA4 6/4885SMN1; SMN2 534/4885HTT 898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.